ARIAD Pharmaceuticals, Inc.
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
Published in Law and Health Weekly, January 9th, 2010
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas. The Company believes that this international study is the largest clinical trial to be conducted in patients with sarcomas. It was initiated in September, 2007 and took just over two years to fully accrue.
"We are extremely proud of this accomplishment," stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Achieving full patient enrollment in the SUCCEED clinical trial was a major global undertaking,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- AARP Idaho
AARP Idaho Applauds Senate for Moving Health Care Reform Forward - AARP Idaho
Health Care Reform Moves One Step Closer to Bringing Relief to Idaho Families - AARP Maryland
AARP Maryland Applauds Senate for Moving Health Care Reform Forward - AARP Pennsylvania
AARP Thanks Senate for Passing Health Care Reform - Acacia Research Corporation
Acacia Subsidiary Licenses Medical Picture Archiving and Communication System PACS Technology to Aspyra - AdMeTech Foundation
Congress Approves Defense Spending Bill Containing $1.6 Million for Pioneering Research to Improve Prostate Cancer Imaging - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
